CROSSJECT : Appoints Henri de Parseval as Supply Chain Director

 

Crossject Appoints Henri de Parseval as

Supply Chain Director

 

Chenôve, October 13^th, 2014, 5.50 pm - CROSSJECT (ISIN : FR0011716265 ; Mnémo :ALCJ), the creator of ZENEO®, the world's most advanced needle-free injection system, announces the appointment of Henri de Parseval as  the Company's first Supply Chain Director. He will be responsible for monitoring the industrialization of ZENEO®'s manufacturing supply chain. The first ZENEO® product is expected to be commercialized in late 2015.

Henri de Parseval joins Crossject with 17 years of experience in supply chain management working for several international groups. During his career he has developed expertise in managing strategic partnerships, purchasing and material flow management, especially at Ansaldo and Michelin. In his last position, he created the supply chain to implement innovative railway safety system for major mining groups 'projects in Australia.

Henri de Parseval has headed restructuring projects and coordinated international operations in several cost oriented industries. He also has a strong know how in supplier's performance management in a challenging regulatory environment.

Henri  is an Ecole Nationale des Arts et Métiers ParisTech graduate.

 

Patrick Alexandre, CEO and Founder of Crossject announces: "I am pleased to welcome Henry de Parseval as the Supply Chain Director for Crossject. In this new role for the Company he will be crucial in Crossjects establishing a supply chain that meets the industry's highest standards. His arrival reinforces our confidence that we will be able to produce ZENEO® on an industrial scale, and bring the first commercial products based, on this unique needle-free device, to the market by the end of 2015 ".

 

Contacts

Crossject

Patrick Alexandre / Timothée Muller

[e-mail]

 

Citigate Dewe Rogerson

Laurence Bault /Lucie Larguier

[phone] / 84 75

[e-mail]

 

[e-mail]

 

About Crossject  ·  www.crossject.com:
http://www.crossject.com/

 

Crossject is using its world-leading needle-free injection system, ZENEO(TM) to develop an attractive pipeline of high value SUPERGENERICS or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.
Crossject's needle-free, pre-filled, single-use ZENEO (TM) injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that ZENEO(TM) can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

 

CROSSJECT is listed on Alternext Paris (Mnemo : ALCJ, ISIN : FR0011716265)

 

PDF Version:
http://hugin.info/160011/R/1862587/653500.pdf

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CROSSJECT via Globenewswire

HUG#1862587